RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
40 hedge funds and large institutions have $7.3M invested in RVL Pharmaceuticals plc Ordinary Shares in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 9 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
3.18% less ownership
Funds ownership: 6.8% → 3.62% (-3.2%)
5% less funds holding
Funds holding: 42 → 40 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
46% less capital invested
Capital invested by funds: $13.6M → $7.3M (-$6.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$364K |
| 2 |
Renaissance Technologies
New York
|
+$320K |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$213K |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$200K |
| 5 |
BlackRock
New York
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.52M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.95M |
| 4 |
Millennium Management
New York
|
-$160K |
| 5 |
Goldman Sachs
New York
|
-$60K |
RVLP Hedge Fund Activity: Q3 2019 in Review
40 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q3 2019, worth a combined $7.3M — down 46% from $13.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RVLP and 7 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 17 added.
The largest buyer was Wedge Capital Management, opening a new position worth an estimated $364K. The largest seller was Great Point Partners, exiting entirely with an estimated $3.52M sold.
- 40 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q3 2019, down from 42 in Q2 2019.
- Funds reported $7.3M of RVL Pharmaceuticals plc Ordinary Shares stock for Q3 2019, down 46% quarter-over-quarter.
- 7 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q3 2019 and 9 closed out, a net change of -2 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q3 2019 was Wedge Capital Management, an estimated $364K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q3 2019 was Great Point Partners, an estimated $3.52M sold.
Based on aggregated 13F filings for Q3 2019.